Avatar
Medscape News source @medscape.com · New York 🇺🇸· 1w

#Epilepsy #MentalHealth #Suicidality

Link Preview
www.medscape.com
Suicidality May Predict Treatment Resistance in Newly Diagnosed Focal Epilepsy
Suicidality at the time of a focal epilepsy diagnosis was associated with a higher risk for future treatment resistance to antiseizure medications (ASMs), independent of concurrent mood or anxiety disorders, a recent cohort study showed.
Avatar
Newsweek News source @newsweek.com · New York 🇺🇸· 2w

#SleepApnea #EpilepsyTreatment #ClinicalTrial

Link Preview
www.newsweek.com
Epilepsy drug could cure sleep apnea -- scientists
An epilepsy drug could be used to help people with sleep apnea, a new study has found. A European clinical trial found that sulthiame, a drug used in the treatment of epilepsy, reduced breathing interruptions in moderate to severe obstructive sleep apnea and improved overnight oxygen levels.
Avatar
CBS News News source @cbsnews.com · New York 🇺🇸· 3w

#EpilepsyAwareness #TeenAdvocacy #MentalHealthSupport

Link Preview
www.cbsnews.com
South Florida teen creates movement for others after refusing to allow diagnosis define her
Instead, she turned her adversity into action, creating a movement to make sure other teens facing the same challenges never feel alone.
Avatar

#EpilepsyAwareness #MentalHealth #Inclusion

Link Preview
www.afro.who.int
Breaking barriers, building bridges for Basotho living with epilepsy
Maseru -- For many Basotho living with epilepsy, daily life is shaped not only by seizures but also by the silence and stigma that often surround the condition.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5

#Biotechnology #Epilepsy #ConferenceCall

Link Preview
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET - NEW YORK, Jan.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5

#Biotechnology #Epilepsy #ConferenceCall

Link Preview
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET - NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc.